Sign In
Buy AMAM
$28.00
+0 (+0%)
At Close: Jun 05, 2024
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
01:20pm, Wednesday, 06'th Mar 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger ag
3 Stocks to Buy That Are Up 200% or More in 2024
02:19pm, Friday, 23'rd Feb 2024
With stocks up 200%, you face a dilemma. While you don't want to fight momentum, you also don't want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 20'th Feb 2024
Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopha
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopha
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
02:17pm, Tuesday, 09'th Jan 2024
J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
12:22pm, Monday, 08'th Jan 2024
Shares of engineered therapeutics specialist Ambrx Biopharma (NASDAQ: AMAM ) skyrocketed on Monday following a major announcement. Pharmaceutical and medical technology stalwart Johnson & Johnson (NYS
Cramer's Mad Dash: Ambrx Biopharma Inc.
10:43am, Monday, 08'th Jan 2024
CNBC's Jim Cramer delivers his daily Mad Dash.
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
09:09am, Monday, 08'th Jan 2024
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.
Ambrx Biopharma stock doubles on JNJ deal
08:49am, Monday, 08'th Jan 2024
Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the J
AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders
08:47am, Monday, 08'th Jan 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ambrx Biopharma, Inc. (NASDAQ: AMAM) to Johnson & Johnson for $28.00 per share in cash is
Ambrx Announces Sale to Johnson & Johnson
07:35am, Monday, 08'th Jan 2024
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will ac
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
07:30am, Monday, 08'th Jan 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-sta
The underdogs of 2023: Small-cap stocks that made it big
07:15am, Tuesday, 26'th Dec 2023
In recent years, most reports of assets surging by thousands of percents in relatively short periods come from the crypto market, where various cryptocurrencies – especially smaller altcoins and mem
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
08:48am, Thursday, 14'th Dec 2023
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that the Company will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective
